Designing a clinical space for alpha therapy.
From hot lab to waste decay storage, alpha-emitter programs introduce design choices that differ meaningfully from established beta-based radioligand therapies.
Facility considerations
An honest assessment of current nuclear medicine infrastructure is the starting point. Most centers already running Lu-177 programs have a strong foundation, but alpha programs introduce new contamination-control and waste-storage requirements.
RLT facility needs
Dedicated unit dose receipt, preparation, QC, administration, and recovery workflows — ideally on a controlled, restricted-access circuit.
Patient throughput
Map expected volumes against existing infusion chair time, hot lab capacity, and post-administration hold areas.
Workflow segregation
Separate diagnostic vs therapeutic flows where possible to minimize cross-contamination risk.
Key spaces
A typical alpha-therapy suite includes a hot lab, administration room, post-administration hold, and decay-in-storage area. Each has distinct ventilation, shielding, and access requirements.
Hot lab
Dose preparation, QC, and unit-dose verification. Requires HEPA-ventilated containment, shielded L-blocks, and alpha-capable contamination monitoring.
Administration room
Shielded patient chair or bed, dedicated IV access workflow, and contamination control surfaces. Single-patient occupancy during dosing.
Post-administration hold
Brief monitored hold for vital signs and any acute reactions before discharge. Plan for restroom contamination control.
Waste decay storage
Secured, shielded, ventilated room sized for the full decay chain — Ac-225's daughters extend the practical hold time vs. parent half-life alone.
Shielding for alpha emitters
Alpha particles themselves are stopped by a sheet of paper. The shielding challenge for Ac-225 comes from the decay-chain daughters — which include both beta and gamma emitters — and from contamination control rather than primary external exposure.
External dose drivers
Gamma emissions from daughter isotopes (e.g. Fr-221, Bi-213) drive external dose to staff, not the alpha particles themselves.
Lead vs. tungsten
Lead remains the workhorse for vial and syringe shields; tungsten offers higher density for the same shielded volume where space is constrained.
Contamination as the dominant risk
Inhalation, ingestion, or wound contamination — not external exposure — drives the radiological risk profile. PPE, surface controls, and bioassay matter more than thick walls.
Site readiness assessment
A structured walk-through against the categories below helps a center scope the work required to launch an alpha-therapy program — from minor procedural updates to physical build-out.
License & program
Authorized Users, RSO program, written procedures, training records.
Physical plant
Hot lab, administration room, hold area, decay storage, ventilation.
Equipment
Dose calibrator settings, alpha-capable survey instruments, PPE inventory, spill kits.
Workforce
Nuclear medicine, medical physics, pharmacy, nursing, and environmental services training.